{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:24:19Z","timestamp":1782343459275,"version":"3.54.5"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To estimate the efficacy and safety of mifepristone antagonization with high-dose oral progesterone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We planned to enroll 40 patients in a double-blind, placebo-controlled, randomized trial. We enrolled patients at 44\u201363 days of gestation with ultrasound-confirmed gestational cardiac activity who were planning surgical abortion. Participants ingested mifepristone 200 mg and initiated oral progesterone 400 mg or placebo 24 hours later twice daily for 3 days, then once daily until their planned surgical abortion 14\u201316 days after enrollment. Follow-up visits were scheduled 3\u00b11, 7\u00b11, and 15\u00b11 days after mifepristone intake with ultrasonography and blood testing for human chorionic gonadotropin and progesterone. Participants exited from the study when they had their surgical abortion or earlier for gestational cardiac activity absence, gestational sac expulsion, or medically indicated suction aspiration. We assessed the primary outcome of continued gestational cardiac activity at approximately 2 weeks (15\u00b11 day), side effects after drug ingestion, and safety outcomes including hemorrhage and emergent treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>We enrolled participants from February to July 2019 and stopped enrollment after 12 patients for safety concerns. Mean gestational age was 52.5 days. Two (one per group) voluntarily discontinued 3 days after mifepristone ingestion for subjective symptoms (nausea and vomiting, bleeding). Among the remaining 10 patients (five per group), gestational cardiac activity continued for 2 weeks in four in the progesterone group and two in the placebo group. One patient in the placebo group had no gestational cardiac activity 3 days after mifepristone use. Severe hemorrhage requiring ambulance transport to hospital occurred in three patients; one received progesterone (complete expulsion, no aspiration) and two received placebo (aspiration for both, one required transfusion). We halted enrollment after the third hemorrhage. No other significant side effects were reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>We could not estimate the efficacy of progesterone for mifepristone antagonization due to safety concerns when mifepristone is administered without subsequent prostaglandin analogue treatment. Patients in early pregnancy who use only mifepristone may be at high risk of significant hemorrhage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n            <jats:p>\n                                 ClinicalTrials.gov, NCT03774745.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000003620","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T19:51:58Z","timestamp":1575661918000},"page":"158-165","source":"Crossref","is-referenced-by-count":35,"title":["Mifepristone Antagonization With Progesterone to Prevent Medical Abortion"],"prefix":"10.1097","volume":"135","author":[{"given":"Mitchell D.","family":"Creinin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody Y.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Steward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1056\/NEJM199308053290607","article-title":"Mifepristone (RU 486)\u2014a modulator of progestin and glucocorticoid action","volume":"329","author":"Spitz","year":"1993","journal-title":"N Engl J Med"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0015-0282(97)00189-1","article-title":"Mifepristone (RU486): a review","volume":"68","author":"Mahajan","year":"1997","journal-title":"Fertil Steril"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.contraception.2019.05.006","article-title":"Medical abortion with mifepristone and vaginal misoprostol between 64 and 70\u202fdays' gestation","volume":"100","author":"Hsia","year":"2019","journal-title":"Contraception"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1345\/aph.1R252","article-title":"Progesterone use to reverse the effects of mifepristone","volume":"46","author":"Delgado","year":"2012","journal-title":"Ann Pharmacother"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/13625187.2017.1412424","article-title":"Progesterone for preventing pregnancy termination after initiation of medical abortion with mifepristone","volume":"22","author":"Garratt","year":"2017","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R8-20230711","first-page":"3","article-title":"A case series detailing the successful reversal of the effects of mifepristone using progesterone","volume":"33","author":"Delgado","year":"2018","journal-title":"Issues Law Med"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.contraception.2015.06.001","article-title":"Continuing pregnancy after mifepristone and \u201creversal\u201d of first-trimester medical abortion: a systematic review","volume":"92","author":"Grossman","year":"2015","journal-title":"Contraception"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7863\/jum.1994.13.1.27","article-title":"Endovaginal ultrasonographic measurement of early embryonic size as a means of assessing gestational age","volume":"13","author":"Goldstein","year":"1994","journal-title":"J Ultrasound Med"},{"key":"R11-20230711","first-page":"1089","article-title":"Early pregnancy interruption using an antiprogesterone steroid: mifepristone (RU 486)","volume":"17","author":"Maria","year":"1988","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/AOG.0000000000000603","article-title":"Incidence of emergency department visits and complications after abortion","volume":"125","author":"Upadhyay","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0010-7824(87)90088-6","article-title":"Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications\u2014a review","volume":"36","author":"Sitruk-Ware","year":"1987","journal-title":"Contraception"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/1471-0528.12147","article-title":"Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study","volume":"120","author":"Bernard","year":"2013","journal-title":"BJOG"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/humrep\/der130","article-title":"Ultrasonographic prediction of early miscarriage","volume":"26","author":"Papaioannou","year":"2011","journal-title":"Hum Reprod"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T19:43:09Z","timestamp":1689104589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003620"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003620","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,3]]}}}